Relmada Regains Compliance with Nasdaq Minimum Bid Price Requirement
Relmada Therapeutics, Inc. (RLMD)
NASDAQ:AMEX Investor Relations:
ir.relmada.com
Company Research
Source: GlobeNewswire
CORAL GABLES, Fla., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology-related and central nervous system indications, today announced that on September 15, 2025 it received written notice from the Nasdaq Stock Market LLC (Nasdaq) confirming that the Company has regained compliance with Nasdaq’s $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550 (a)(2) (the “Listing Rule”). To regain compliance with the Listing Rule, the Company’s shares were required to maintain a minimum closing bid price of $1.00 for at least 10 consecutive business days, which was achieved on September 12, 2025. As a result, Nasdaq has closed the matter. Relmada is now in full compliance with all Nasdaq continued listing requirements, and the Company’s stock will remain listed and traded on the Nasdaq Capital Market under the ticker “RLMD.” About Relmada The
Show less
Read more
Impact Snapshot
Event Time:
RLMD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RLMD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RLMD alerts
High impacting Relmada Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
RLMD
News
- Relmada Therapeutics Announces Presentation of NDV-01 Phase 2 Data at the Society for Urologic OncologyGlobeNewswire
- Relmada Therapeutics (NASDAQ:RLMD) was upgraded by analysts at Mizuho from a "neutral" rating to an "outperform" rating. They now have a $10.00 price target on the stock.MarketBeat
- Relmada Therapeutics GAAP EPS of -$0.30 [Seeking Alpha]Seeking Alpha
- Relmada Therapeutics to Report Third Quarter 2025 Financial Results on Thursday, November 13, 2025GlobeNewswire
- Relmada Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock and Pre-Funded WarrantsGlobeNewswire
RLMD
Earnings
- 11/13/25 - Miss
RLMD
Sec Filings
- 11/14/25 - Form SCHEDULE
- 11/6/25 - Form 4
- 11/6/25 - Form 4
- RLMD's page on the SEC website